Olive Leaf Cholesterol Meta-analysis: What the Evidence Says
Olive Leaf Cholesterol Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are ra
Quick Answer
Olive Leaf Cholesterol Meta analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence aware guidance rather than medical advice.
Key Takeaways
- 01This page is generated only from sources stored in the Migaku evidence knowledge base.
- 02Current evidence mix: 1 randomized trial, 1 research article.
- 03Claims should be interpreted with the source type, study design, population, and publication date in mind.
- 04This article is educational and does not replace care from a qualified clinician.
Olive Leaf Cholesterol Meta-analysis: What the Evidence Says
Quick Answer
Olive Leaf Cholesterol Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.
Key Takeaways
- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 1 randomized trial, 1 research article.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.
Evidence Map
| Source | Evidence type | Level | Date | Identifier |
|---|---|---|---|---|
| Evaluation of the effect of olive extracts on blood pressure and cardiovascular health markers in adults: Findings from a double-blind, placebo-controlled, randomised trial | randomized trial | 2 | 2026-03-10 | 10.1371/journal.pone.0344278 |
| Editorial: Preventing cardiovascular complications of type 2 diabetes, volume II | research article | 4 | 2026-01-29 | 10.3389/fendo.2026.1792059 |
What The Sources Report
- The declining CVD mortality rate that was observed remained stable in the last years or even increased in some populations. [Lauwers Stef (2026); evidence level 2]
- Poor management of factors, such as diet, physical activity, blood lipids, and blood pressure, will increase the risk of developing CVD as a 20 mmHg increase in systolic blood pressure (SBP) is associated with a doubled risk of death from CVD. [Lauwers Stef (2026); evidence level 2]
- Diabetes mellitus represents a major global health challenge, with a rapidly increasing prevalence worldwide, and is associated with a markedly elevated risk of adverse health outcomes, particularly cardiovascular disease (CVD). [Di Pietrantonio Nadia (2026); evidence level 4]
- The search for new strategies to prevent diabetes and its cardiovascular complications increasingly emphasizes the identification of novel biomarkers and the re-evaluation of established ones, aiming to enable earlier and more precise risk assessment. [Di Pietrantonio Nadia (2026); evidence level 4]
How To Read This Evidence
Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.
Practical Interpretation
There is trial evidence in the current set, but population and intervention details still matter. For olive leaf cholesterol meta-analysis, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.
Limits Of This First Pass
This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.
References
- Lauwers Stef (2026). Evaluation of the effect of olive extracts on blood pressure and cardiovascular health markers in adults: Findings from a double-blind, placebo-controlled, randomised trial. DOI: 10.1371/journal.pone.0344278. PMCID: PMC12974854. PMID: 41805711. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12974854/
- Di Pietrantonio Nadia (2026). Editorial: Preventing cardiovascular complications of type 2 diabetes, volume II. DOI: 10.3389/fendo.2026.1792059. PMCID: PMC12893936. PMID: 41694573. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC12893936/
Safety Note
Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.
FAQ
Frequently Asked Questions
Medically reviewed
Last reviewed July 6, 2026 by Migaku Evidence Review
